Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Cancer. 2011 Mar 28;117(19):4375–4380. doi: 10.1002/cncr.26078

Figure 4.

Figure 4

Sensitivity to TRAIL and resistance to doxorubicin conferred by expression of His64 galectin-3 but not Pro64 galectin-3. Parental BT549 cells and BT549 transfectants expressing vehicle plasmid (BT and VC, open bars) or transfectants expressing His64 galectin-3 (25A and 25B, hashed bars) or Pro64 galectin-3 (25C, B3, and C2, solid bars) were treated 4h with TRAIL (A) or overnight with doxorubicin (B) and cell viability was measured by the MTT assay. Stippled bars represent dead cell in the absence of TRAIL or doxorubicin.